The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
Elevated TnT levels associated with arrhythmias, use of glucocorticoid therapy, mechanical ventilation
More hospitalized patients with cardiac injury required noninvasive or invasive mechanical ventilation.
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Patients advised to continue ACE inhibitors/ARBs after researcher posits risk for severe COVID-19 infection.
The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).
Findings may have important public health implications for chronic disease prevention.
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
Risk for ischemic stroke lower with higher intake of fruit and vegetables, dietary fiber, milk, yogurt, cheese.